Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised trial of doxorubicin versus doxorubicin plus ifosfamide in first-line treatment of advanced or metastatic soft tissue sarcoma
2004-002113-36Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in soft tissue sarcoma (STS) comparing Doxorubicin monotherapy with Doxorubicin plus ifosfamide combination (2 arms). Primary endpoint: Overall survival. Started Jun 2006; status: completed.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2004-002113-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002113-36.